In one paragraphArticle in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Margherita RomeoDepartment of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.
Sara BaroniDepartment of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.ORCID 0000-0001-6649-3846 Maria Monica BarzagoDepartment of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.ORCID 0000-0002-6952-0069 Samuela GambiniDepartment of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.
Ada De LuigiDepartment of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.ORCID 0000-0001-7907-7139 Daniela IaconisEXSCALATE, Dompé Farmaceutici SpA, Via Tommaso De Amicis, 95, 80131 Napoli, Italy.
Andrea Rosario BeccariEXSCALATE, Dompé Farmaceutici SpA, Via Tommaso De Amicis, 95, 80131 Napoli, Italy.ORCID 0000-0001-6830-2695 Maddalena FratelliDepartment of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.ORCID 0000-0002-1769-3427 Luisa DiomedeDepartment of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.ORCID 0000-0002-2258-0531 Funding
Enhancing and expanding the CGC Strain CollectionP40OD010440 · OD · UNIVERSITY OF MINNESOTA · PI Ann E. Rougvie · 2012 to 2026
$7.5MEuropean Union Horizon 2020 European Project N.101003551-EXSCALATE4CoVEuropean Union NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases , Project no. PE00000007, INF-ACTNIH HHS P40 OD010440
6 · The paper itselfAbstract
Testing medical countermeasures for SARS-CoV-2 transmission using vertebrates can be hindered by legislation regulating animal experimentation, high costs, and ethical concerns. To overcome these challenges, we propose a new
Indexed as
Angiotensin-Converting Enzyme 2Caenorhabditis elegansSARS-CoV-2Virus InternalizationAnimalsCOVID-19COVID-19 Drug TreatmentHEK293 CellsHumansSpike Glycoprotein, CoronavirusACE2 protein, humanAngiotensin-Converting Enzyme 2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2angiotensin-converting enzyme 2C. elegansCOVID-19pseudo infectionraloxifenereceptor binding domainSARS-CoV-2
Identifiers
PMID41157657
PMCPMC12567688
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390